From the Hypotheses to Clinical Evidence in Retinal Therapy

Overview

Journal J Ophthalmic Vis Res

Specialty Ophthalmology

Date 2021 May 31

PMID 34055265

Authors

Bradley Beatson

J Fernando Arevalo

Affiliations

Soon will be listed here.

Abstract

The off-label, therapeutic use of intravitreal bevacizumab (IVB) in vascular retinal diseases such as diabetic macular edema and proliferative diabetic retinopathy (PDR) has increased significantly due to its ability to reduce retinal neovascularization and slow progression of disease. Here, we will review the literature and investigative developments on the use of IVB as a preoperative adjuvant to vitrectomy in severe PDR, specifically focusing on its ability to reduce intra- and postoperative complications and its risk for progression or development of traction retinal detachment. In particular, this review will highlight the natural progression of evidence from case series and observations to prospective, randomized clinical trials.

References

Anothaisintawee T, Leelahavarong P, Ratanapakorn T, Teerawattananon Y . The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand's pharmaceutical benefit package. Clinicoecon Outcomes Res. 2012; 4:361-74. PMC: 3520463. DOI: 10.2147/CEOR.S37458. View

Zhang X, Saaddine J, Chou C, Cotch M, Cheng Y, Geiss L . Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA. 2010; 304(6):649-56. PMC: 2945293. DOI: 10.1001/jama.2010.1111. View

Hutton D, Newman-Casey P, Tavag M, Zacks D, Stein J . Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period. Health Aff (Millwood). 2014; 33(6):931-9. PMC: 4137040. DOI: 10.1377/hlthaff.2013.0832. View

Avery R, Pearlman J, Pieramici D, Rabena M, Castellarin A, Nasir M . Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006; 113(10):1695.e1-15. DOI: 10.1016/j.ophtha.2006.05.064. View

Gross J, Glassman A, Jampol L, Inusah S, Aiello L, Antoszyk A . Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA. 2015; 314(20):2137-2146. PMC: 5567801. DOI: 10.1001/jama.2015.15217. View

Solomon S, Chew E, Duh E, Sobrin L, Sun J, VanderBeek B . Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017; 40(3):412-418. PMC: 5402875. DOI: 10.2337/dc16-2641. View

Jonas J, Schmidbauer M, Rensch F . Progression of tractional retinal detachment following intravitreal bevacizumab. Acta Ophthalmol. 2008; 87(5):571-2. DOI: 10.1111/j.1755-3768.2008.01225.x. View

Sun J, Glassman A, Beaulieu W, Stockdale C, Bressler N, Flaxel C . Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy. Ophthalmology. 2018; 126(1):87-95. PMC: 6916649. DOI: 10.1016/j.ophtha.2018.08.001. View

Chen E, Park C . Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. 2006; 26(6):699-700. DOI: 10.1097/01.iae.0000225351.87205.69. View

10.

Fernando Arevalo J, Sanchez J, Saldarriaga L, Berrocal M, Fromow-Guerra J, Morales-Canton V . Retinal detachment after bevacizumab. Ophthalmology. 2011; 118(11):2304.e3-7. DOI: 10.1016/j.ophtha.2011.05.015. View

11.

Zhao L, Zhu H, Zhao P, Hu Y . A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol. 2011; 95(9):1216-22. PMC: 3161500. DOI: 10.1136/bjo.2010.189514. View

12.

Grisanti S, Ziemssen F . Bevacizumab: off-label use in ophthalmology. Indian J Ophthalmol. 2007; 55(6):417-20. PMC: 2635984. DOI: 10.4103/0301-4738.36474. View

13.

Nicoletti V, Nicoletti R, Ferrara N, Meli G, Reibaldi M, Reibaldi A . Diabetic patients and retinal proliferation: an evaluation of the role of vascular endothelial growth factor (VEGF). Exp Clin Endocrinol Diabetes. 2003; 111(4):209-14. DOI: 10.1055/s-2003-40465. View

14.

Yau J, Rogers S, Kawasaki R, Lamoureux E, Kowalski J, Bek T . Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012; 35(3):556-64. PMC: 3322721. DOI: 10.2337/dc11-1909. View

15.

Sivaprasad S, Prevost A, Vasconcelos J, Riddell A, Murphy C, Kelly J . Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase.... Lancet. 2017; 389(10085):2193-2203. DOI: 10.1016/S0140-6736(17)31193-5. View

16.

Fernando Arevalo J, Lasave A, Kozak I, Al Rashaed S, Al Kahtani E, Maia M . Preoperative Bevacizumab for Tractional Retinal Detachment in Proliferative Diabetic Retinopathy: A Prospective Randomized Clinical Trial. Am J Ophthalmol. 2019; 207:279-287. DOI: 10.1016/j.ajo.2019.05.007. View

17.

Aiello L, Avery R, Arrigg P, Keyt B, Jampel H, Shah S . Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331(22):1480-7. DOI: 10.1056/NEJM199412013312203. View

18.

Adamis A, Miller J, Bernal M, DAmico D, Folkman J, Yeo T . Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994; 118(4):445-50. DOI: 10.1016/s0002-9394(14)75794-0. View

19.

Arevalo J, Maia M, Flynn Jr H, Saravia M, Avery R, Wu L . Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2007; 92(2):213-6. DOI: 10.1136/bjo.2007.127142. View